Panelists discuss how step-up dosing protocols reduce cytokine release syndrome (CRS) risk in patients with high-risk disease ...

Panelists discuss the most common logistical challenges encountered when implementing bispecific therapies in both academic ...

Panelist discusses how patient advocacy groups act as critical bridges between patients, researchers, and health care providers, ultimately improving recognition, treatment, and quality of life for ...

Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

Adam Colborn, JD, of AMCP, discussed how President Trump's rescission of several Biden-era executive orders may impact ...

A genetic causal link between rheumatoid arthritis (RA) and an increased risk of traumatic and osteoporotic fractures ...

A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.

The asymptomatic nature of glaucoma makes it imperative to get consistent screening to catch the condition early.

A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining ...

Medicare Advantage enrollees, particularly Hispanic and Asian or Pacific Islander decedents, use less end-of-life home health care than those enrolled in traditional Medicare.

Results from a case series identified a potential association between ophthalmic complications and the rapid correction of hyperglycemia, brought on by patients using either semaglutide or tirzepatide ...